Literature DB >> 23665667

Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity.

Wenjin Guo1, Brad Cleveland, Thaddeus M Davenport, Kelly K Lee, Shiu-Lok Hu.   

Abstract

Vaccinia virus (VV) has been used to express a variety of heterologous proteins, including HIV envelope (Env) glycoproteins. The Env protein is synthesized as a precursor molecule, gp160, which is cleaved into the surface antigen gp120 and the transmembrane protein gp41. Even though production of gp160 by the VV expression system has been described, its use for gp120 production is not well documented. Here we report a new procedure for the purification of gp120 from serum-containing culture supernatant of VV-infected cells. The gp120 protein was enriched to a purity better than 60% on a snowdrop (Galanthus nivalis) lectin affinity column in the presence of 0.25% zwitterionic detergent Empigen BB. After additional DEAE anion exchange and Superdex size exclusion chromatography steps, the gp120 monomer was purified free of contamination as determined by SDS-PAGE. The retention of structural integrity was confirmed by determining the affinity constant of purified gp120s to soluble CD4 and a monoclonal antibody IgG1b12, using surface plasmon resonance analysis. The purification procedure is robust and reproducible, and may find general use for glycoprotein purifications from sources where the presence of serum is desirable.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665667      PMCID: PMC3718289          DOI: 10.1016/j.pep.2013.04.009

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  49 in total

1.  Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells.

Authors:  Andrés Finzi; Beatriz Pacheco; Xin Zeng; Young Do Kwon; Peter D Kwong; Joseph Sodroski
Journal:  J Virol Methods       Date:  2010-05-13       Impact factor: 2.014

2.  Empigen BB: a useful detergent for solubilization and biochemical analysis of keratins.

Authors:  L A Lowthert; N O Ku; J Liao; P A Coulombe; M B Omary
Journal:  Biochem Biophys Res Commun       Date:  1995-01-05       Impact factor: 3.575

Review 3.  HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Eric O Freed
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

4.  Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses.

Authors:  G Gilljam
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

5.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

Authors:  D R Burton; C F Barbas; M A Persson; S Koenig; R M Chanock; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

6.  Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.

Authors:  Samir K Lakhashe; Vijayakumar Velu; Gaia Sciaranghella; Nagadenahalli B Siddappa; Janet M Dipasquale; Girish Hemashettar; John K Yoon; Robert A Rasmussen; Feng Yang; Sandra J Lee; David C Montefiori; Francis J Novembre; François Villinger; Rama Rao Amara; Maria Kahn; Shiu-Lok Hu; Sufen Li; Zhongxia Li; Fred R Frankel; Marjorie Robert-Guroff; Welkin E Johnson; Judy Lieberman; Ruth M Ruprecht
Journal:  Vaccine       Date:  2011-07-14       Impact factor: 3.641

7.  Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.

Authors:  S L Hu; J Klaniecki; T Dykers; P Sridhar; B M Travis
Journal:  AIDS Res Hum Retroviruses       Date:  1991-07       Impact factor: 2.205

8.  Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

Authors:  S L Hu; K Abrams; G N Barber; P Moran; J M Zarling; A J Langlois; L Kuller; W R Morton; R E Benveniste
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

9.  Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Authors:  E L Cooney; M J McElrath; L Corey; S L Hu; A C Collier; D Arditti; M Hoffman; R W Coombs; G E Smith; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

10.  Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160.

Authors:  S Hallenberger; V Bosch; H Angliker; E Shaw; H D Klenk; W Garten
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

View more
  6 in total

1.  Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.

Authors:  Samantha Townsley; Yun Li; Yury Kozyrev; Brad Cleveland; Shiu-Lok Hu
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

2.  Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.

Authors:  Rajesh Thippeshappa; Baoping Tian; Brad Cleveland; Wenjin Guo; Patricia Polacino; Shiu-Lok Hu
Journal:  Clin Vaccine Immunol       Date:  2015-12-30

3.  Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.

Authors:  Thaddeus M Davenport; Miklos Guttman; Wenjin Guo; Brad Cleveland; Maria Kahn; Shiu-Lok Hu; Kelly K Lee
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

4.  Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Authors:  Samantha Townsley; Zeinab Mohamed; Wenjin Guo; Jennifer McKenna; Brad Cleveland; Celia LaBranche; David Beaumont; Xiaoying Shen; Nicole L Yates; Abraham Pinter; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Shiu-Lok Hu
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

5.  Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.

Authors:  Norbert Pardi; Michael J Hogan; Martin S Naradikian; Kaela Parkhouse; Derek W Cain; Letitia Jones; M Anthony Moody; Hans P Verkerke; Arpita Myles; Elinor Willis; Celia C LaBranche; David C Montefiori; Jenna L Lobby; Kevin O Saunders; Hua-Xin Liao; Bette T Korber; Laura L Sutherland; Richard M Scearce; Peter T Hraber; István Tombácz; Hiromi Muramatsu; Houping Ni; Daniel A Balikov; Charles Li; Barbara L Mui; Ying K Tam; Florian Krammer; Katalin Karikó; Patricia Polacino; Laurence C Eisenlohr; Thomas D Madden; Michael J Hope; Mark G Lewis; Kelly K Lee; Shiu-Lok Hu; Scott E Hensley; Michael P Cancro; Barton F Haynes; Drew Weissman
Journal:  J Exp Med       Date:  2018-05-08       Impact factor: 17.579

6.  Saturation Mutagenesis of the HIV-1 Envelope CD4 Binding Loop Reveals Residues Controlling Distinct Trimer Conformations.

Authors:  Maria Duenas-Decamp; Li Jiang; Daniel Bolon; Paul R Clapham
Journal:  PLoS Pathog       Date:  2016-11-07       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.